Eastern Cooperative Oncology Group (Main Institution)

东部肿瘤合作组(主要机构)

基本信息

项目摘要

DESCRIPTION (provided by applicant): The University of Pittsburgh Cancer Institute (UPCI) was formed in 1985, and over the twenty-three years since then has amassed a cadre of more than 400 basic and clinical investigators with broad basic and clinical expertise that relates to the ECOG in relation to many of its disease and modality committees. The Eastern Cooperative Oncology Group (ECOG) is the major extramural focus of multi-modal clinical investigations in adult solid tumors of the UPCI. UPCI is based in the hospitals of the University of Pittsburgh Medical Center (UPMC), a health system consisting of UPMC Presbyterian (PUH), UPMC Montefiore (MUH), the Eye and Ear Hospital and Institute, UPMC Shadyside Hospital, Western Psychiatric Hospital and Clinic, Falk Clinic, and the Magee Women's Hospital. In 2002, The UPMC Cancer Centers were formed, including a broad array of more than 45 locations that serve as the base of operations for full-time and clinical faculty of the UPCI who are active in ECOG within Pittsburgh and across the region. These include UPMC Shadyside, UPMC Bedford Memorial, UPMC Braddock, UPMC Horizon-Greenville and Shenango Valley, UPMC Lee Regional, UPMC McKeesport, UPMC Northwest Franklin and Oil City, UPMC Passavant, Cranberry, UPMC Southside, Children's Hospital of Pittsburgh, UPMC St. Margaret's, UPMC Mercy, Magee Women's Hospital, Beaver Valley, Latrobe Area Hospital, Heritage Valley Health System, Westmorland Hospital, Jameson Health System, Jefferson Regional Medical Center, Memorial Medical Center, The Washington Hospital, Uniontown Hospital and Frick Hospital as well as the UPMC Rehabilitation Hospital. These facilities provide for a cachement area that extends across Western Pennsylvania from W. Virginia to Ohio and New York State. The Oakland Veterans Administration Medical Center is a consortium member of ECOG, affording access to ECOG studies for patients of the VA system. UPMC relocated inpatient UPCI clinical facilities to MUH in 1993, and to the Hillman Cancer Center - UPMC Shadyside Medical Center in 2003, with full service inpatient Medical Oncology, Surgical Oncology, and Hematology/BMT as well as a satellite Clinical Translational Science Institute (CTSI) in the outpatient Hillman Cancer Center Ambulatory Care Facility. A range of ECOG studies with laboratory components are being conducted on this CTSI, providing support for protocol therapy of patients on ECOG trials beyond what would be possible with third party payer coverage. The basic cancer research space of UPCI has been consolidated in the Hillman Cancer Center Research Pavilion that was completed in 2002, offering state-of-the-art research laboratories contiguous with the outpatient and inpatient facilities. Those that relate directly to ECOG include the Clinical Immunologic Monitoring Laboratory (IMCPL) which serves as the Core Immunological Monitoring Laboratory for ECOG, the Serum and Tissue Bank, and Flow Cytometry FACS/Hybridoma facilities. Separately located on the campus of the UPMC are Crystallography, Peptide Synthesis, and Oligonucleotide Synthesis facilities. The Clinical Research Services are now located in the Hillman Cancer Center Cooper Ambulatory Pavilion, while the Biostatistical Office is located at the Sterling Building several blocks closer to the Oakland Campus. UPCI and UPMC have developed as matrix organizations in which the traditional academic departments and divisions of Hematology/Oncology, Surgical Oncology, and Radiation Oncology are configured along disease-oriented lines to facilitate the growth and development of interdisciplinary disease-oriented and modality programs. RELEVANCE: The Eastern Cooperative Oncology Group (ECOG) is the major extramural focus of multi-modal clinical Investigations In adult solid tumors of the UPCI. UPCI is based in the hospitals of the University of Pittsburgh Medical Center (UPMC).
描述(由申请人提供):匹兹堡大学癌症研究所 (UPCI) 成立于 1985 年,从那时起的 23 年里,已经聚集了 400 多名基础和临床研究人员,他们拥有与 ECOG 及其许多疾病和模式委员会相关的广泛基础和临床专业知识。东部肿瘤合作组 (ECOG) 是 UPCI 成人实体瘤多模式临床研究的主要外部焦点。 UPCI 总部位于匹兹堡大学医学中心 (UPMC) 的医院,该医疗系统由 UPMC Presbyterian (PUH)、UPMC Montefiore (MUH)、眼耳医院和研究所、UPMC Shadyside 医院、西部精神病医院和诊所、Falk 诊所和 Magee 妇女医院组成。 2002 年,UPMC 癌症中心成立,包括超过 45 个地点,作为活跃于匹兹堡和整个地区 ECOG 的 UPCI 全职和临床教员的运营基地。其中包括 UPMC Shadyside、UPMC Bedford Memorial、UPMC Braddock、UPMC Horizo​​n-Greenville 和 Shenango Valley、UPMC Lee Regional、UPMC McKeesport、UPMC 西北富兰克林和石油城、UPMC Passavant、Cranberry、UPMC Southside、匹兹堡儿童医院、UPMC 圣玛格丽特医院、UPMC Mercy、Magee Women's Hospital、Beaver Valley、Latrobe Area Hospital、Heritage Valley Health System、Westmorland Hospital、Jameson Health System、Jefferson Regional Medical Center、Memorial Medical Center、The Washington Hospital、Uniontown Hospital 和 Frick Hospital 以及 UPMC Rehabilitation Hospital。这些设施提供了一个从西弗吉尼亚州延伸到俄亥俄州和纽约州的整个宾夕法尼亚州西部的缓存区。奥克兰退伍军人管理局医疗中心是 ECOG 联盟成员,为 VA 系统的患者提供 ECOG 研究。 UPMC 于 1993 年将住院 UPCI 临床设施迁至 MUH,并于 2003 年迁往 Hillman 癌症中心 - UPMC Shadyside 医疗中心,提供住院肿瘤内科、肿瘤外科和血液学/BMT 全方位服务,并在 Hillman 癌症中心门诊门诊设施中设有卫星临床转化科学研究所 (CTSI)。在此 CTSI 上正在进行一系列包含实验室组成部分的 ECOG 研究,为 ECOG 试验中患者的方案治疗提供超出第三方付款人承保范围的支持。 UPCI 的基础癌症研究空间已整合到 2002 年竣工的希尔曼癌症中心研究馆中,提供毗邻门诊和住院设施的最先进的研究实验室。与 ECOG 直接相关的实验室包括作为 ECOG 核心免疫监测实验室的临床免疫监测实验室 (IMCPL)、血清和组织库以及流式细胞术 FACS/杂交瘤设施。 UPMC 校园内分别设有晶体学、肽合成和寡核苷酸合成设施。临床研究服务部现位于希尔曼癌症中心库珀流动馆,而生物统计办公室位于距奥克兰校区几个街区的斯特林大楼。 UPCI 和 UPMC 已发展成为矩阵组织,其中血液学/肿瘤学、外科肿瘤学和放射肿瘤学的传统学术部门和部门按照疾病导向的路线进行配置,以促进跨学科的疾病导向和模式项目的成长和发展。 相关性:东部肿瘤合作组 (ECOG) 是 UPCI 成人实体瘤多模式临床研究的主要外部焦点。 UPCI 位于匹兹堡大学医学中心 (UPMC) 的医院内。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates.
干扰素-α 在头颈局部复发或转移性鳞状细胞癌中的 II 期试验:免疫学和临床相关性。
New challenges in endpoints for drug development in advanced melanoma.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Munn Kirkwood其他文献

John Munn Kirkwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Munn Kirkwood', 18)}}的其他基金

Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10270227
  • 财政年份:
    2021
  • 资助金额:
    $ 20.05万
  • 项目类别:
Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10469631
  • 财政年份:
    2021
  • 资助金额:
    $ 20.05万
  • 项目类别:
Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10683750
  • 财政年份:
    2021
  • 资助金额:
    $ 20.05万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    9272850
  • 财政年份:
    2014
  • 资助金额:
    $ 20.05万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    8607635
  • 财政年份:
    2014
  • 资助金额:
    $ 20.05万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    8857377
  • 财政年份:
    2014
  • 资助金额:
    $ 20.05万
  • 项目类别:
Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane
试点临床
  • 批准号:
    8302813
  • 财政年份:
    2012
  • 资助金额:
    $ 20.05万
  • 项目类别:
Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane
试点临床
  • 批准号:
    8509629
  • 财政年份:
    2012
  • 资助金额:
    $ 20.05万
  • 项目类别:
SPORE in Skin Cancer
皮肤癌中的孢子
  • 批准号:
    8548580
  • 财政年份:
    2008
  • 资助金额:
    $ 20.05万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8933150
  • 财政年份:
    2008
  • 资助金额:
    $ 20.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了